Inmaculada Heras

Inmaculada Heras

Auto-generated profile, based on publicly available information

Inmaculada Heras

29Hematology Division, Hospital Morales Meseguer, Murcia, Spain

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 March 2023 in European Journal of Haematology
Verified
Journal Article
Closed access
CCChristelle Ferra Coll
Christelle Ferra Coll
MFMireia Morgades de la Fe
Mireia Morgades de la Fe
LGLaura Prieto García
Laura Prieto García
CPCarlos Costa Pinho
Carlos Costa Pinho
MFMaría Inmaculada Heras Fernando
María Inmaculada Heras Fernando
JRJose-Maria Ribera
Jose-Maria Ribera

12 June 2024 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
MKmi kwon
mi kwon
IGIgnacio Gómez-Centurión
Ignacio Gómez-Centurión
GOGillen Oarbeascoa
Gillen Oarbeascoa
MTMelissa Torres
Melissa Torres
AMAriadna Perez Martinez
Ariadna Perez Martinez
CSCarlos Solano
Carlos Solano
Invasive fungal infections (IFI) pose a significant complication after hematopoietic stem cell transplantation (HSCT). Isavuconazole (ISV) is a new generation azole with a favourable adverse effect and interaction profile approved for the treatment of invasive aspergillosis and mucormycosis. We analysed the indications, effectiveness, adverse event profile and drug interaction management of ISV in the real-world setting in adults who received allogeneic-HSCT (allo-HSCT) within the Spanish Group of HSCT and Cell Therapy (GETH-TC). We conducted a multicenter retrospective study of all consecutive adult allo-HSCT recipients (≥18 years) who received ISV either for IFI treatment or prophylaxis, from December 2017 to August 2021, in 20 centers within the Spanish Group of Hematopoietic Stem Cell Transplantation and Cell Therapy (GETH-TC). 166 adult allografted patients who received ISV from 2017 to 2021 were included. Median age was 48 years with 43% females. In 81 (49%) patients, ISV was used for treatment of IFI, and in 85 (51%) for prophylaxis. Median duration of ISV administration for IFI treatment was 57 days (range 31-126) and 86 days (range 33-196) for prophylaxis. Most frequent indication for treatment was invasive aspergillosis (78%), followed by mucormycosis (6%). Therapeutic success (45%) was the most frequent reason for ISV withdrawal. In the prophylaxis group, the resolution of IFI risk factors was the most frequent reason for withdrawal (62%). Six (7%) breakthrough IFI were reported. The majority of patients (80%) presented pharmacological interactions. Twenty one patients (13%) reported adverse events related to ISV, mainly liver biochemistry abnormalities, that lead to ISV withdrawal in 7 patients (4%). ISV was effective and well tolerated for IFI treatment and prophylaxis, with a manageable interaction profile.

11 March 2026 in Blood Advances
Verified
Journal Article
Open access
MPMarta Peña
Marta Peña
GLGiulia Losi
Giulia Losi
VGVictor Navarro Garcés
Victor Navarro Garcés
DQDavid A. Qualls
David A. Qualls
JCJennifer L. Crombie
Jennifer L. Crombie
AMAlberto Mussetti
Alberto Mussetti
Bispecific antibodies (BsAb) targeting CD20 and CD3 have shown efficacy for relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL), but their impact on outcomes following allogeneic hematopoietic cell transplantation (alloHCT) remains unclear. In this international, retrospective study, we compared outcomes of adult patients with R/R B-NHL undergoing first alloHCT after BsAb exposure (n = 47) versus a historical BsAb-naïve cohort (n = 101). Baseline imbalances were addressed using inverse probability of treatment weighting (IPTW) and propensity score matching (PSM). The primary end point was nonrelapse mortality (NRM); secondary end points included overall survival (OS), progression-free survival (PFS), cumulative incidence of relapse (CIR), graft-versus-host disease (GVHD), engraftment, and GVHD/relapse-free survival (GRFS). In the overall cohort, 2-year NRM did not differ significantly between BsAb-exposed and BsAb-naïve groups (IPTW: 29.1% vs 31.4%, P = 0.80; PSM: 35.8% vs. 27.9%, P = 0.43). CIR was significantly lower in BsAb-exposed patients after IPTW (7.4% vs 20.0%, P = 0.01), but not in PSM (9.5% vs 23.4%, P = 0.06). OS, GVHD, GRFS, and engraftment were comparable. In a prespecified subanalysis limited to large B-cell lymphomas, CIR differences were consistent across IPTW (6.1% vs 21.1%, P = 0.01) and PSM (9.2% vs 33.3%, P = 0.03), reinforcing a potential benefit of prior BsAb therapy. A significant improvement in PFS was observed in this subgroup with IPTW (55.5% vs 36.6%; P = 0.04), but not in PSM (P = 0.20). Prior BsAb exposure does not adversely impact alloHCT safety and may be associated with improved disease control. Prospective studies are warranted to define optimal sequencing in this high-risk population.

17 September 2026 in Bone Marrow Transplantation
Verified
Journal Article
Closed access
PDF file
HBHOSPITAL CLINIC OF BARCELONA
HOSPITAL CLINIC OF BARCELONA
LBLeyre Bento
Leyre Bento
MSMaria Queralt Salas
Maria Queralt Salas
JMJuan Montoro
Juan Montoro
JSJaime Sanz
Jaime Sanz
MJManuel Jurado
Manuel Jurado

13 August 2026 in Transplantation and Cellular Therapy
Verified
Journal Article
Closed access
SFSara Fernández-Luis
Sara Fernández-Luis
MGMónica Baile González
Mónica Baile González
AAAlejandro Avendaño
Alejandro Avendaño
CACristina Alburquerque-Prieto
Cristina Alburquerque-Prieto
LSLucrecia Yáñez San Segundo
Lucrecia Yáñez San Segundo
IGIrene García-Cadenas
Irene García-Cadenas